Evidence map›Paper›PMID 36692170›Full record

ArticleJournal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine2023

Emergence of restless legs syndrome during opioid discontinuation.

Stuart J McCarter, Joshua R Labott, Mridul K Mazumder, Judy Gebhard, Julie L Cunningham, Larissa L Loukianova, Wesley P Gilliam, Melissa C Lipford

Open access · bronzeAbstract read
In one paragraph

Article in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Dopaminergic hypersensitivity of the opioid-responsive striatal-entopeduncular pathway in a rodent model of restless legs syndrome.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  2. Article
  3. Article
  4. Opioids and restless legs syndrome: a double-edged sword.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2023
    Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Stuart J McCarterCenter for Sleep Medicine, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Joshua R LabottDepartment of Orthopedics, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Mridul K MazumderDepartment of Geriatric Psychiatry Florida State University, Tallahassee, Florida.
Judy GebhardDepartment of Psychiatry and Psychology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Julie L CunninghamDepartment of Pharmacy and Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Larissa L LoukianovaDepartment of Psychiatry and Psychology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Wesley P GilliamDepartment of Psychiatry and Psychology, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Melissa C LipfordCenter for Sleep Medicine, Mayo Clinic, Mayo Clinic College of Medicine, Rochester, Minnesota.
Mayo Clinic · USFlorida State University · USGTx (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

objectivesThe development of restless legs syndrome (RLS) has been rarely reported during and following opioid withdrawal. We aimed to determine the presence and severity of RLS symptoms during and after supervised opioid tapering.

methodsNinety-seven adults enrolled in the Mayo Clinic Pain Rehabilitation Center who underwent supervised prescription opioid tapering were prospectively recruited. RLS presence and severity was assessed with the Cambridge-Hopkins Questionnaire 13 and International Restless Legs Syndrome Study Group Rating Severity Scale at admission, midpoint, and dismissal from the program as well as 2 weeks, 4 weeks, and 3 months after completion. Frequency and severity of RLS symptoms were compared between admission and each time point.

resultsAverage age of the cohort was 52.6 ± 13.3 years with a morphine milligram equivalent dose for the cohort of 45.6 ± 48.3 mg. Frequency of RLS symptoms increased from 28% at admission to peak frequency of 41% at 2 weeks following discharge from the Mayo Pain Rehabilitation Clinic (

conclusionsModerately severe symptoms of RLS, as assessed by survey, occur commonly in individuals undergoing opioid tapering, particularly if exposed to higher doses. In many cases, symptoms appear to be self-limited, although a minority develop persistent symptoms. Our results may have implications for successful opioid tapering, but future confirmatory studies with structured clinician interview are needed to establish that these symptoms truly represent restless legs syndrome given the potential for RLS-mimicking symptoms in individuals with chronic pain syndromes. CITATION: McCarter SJ, Labott JR, Mazumder MK, et al. Emergence of restless legs syndrome during opioid discontinuation.

Indexed as

Analgesics, OpioidRestless Legs SyndromeAdultAgedHumansMiddle AgedMorphine DerivativesPainSeverity of Illness IndexSurveys and QuestionnairesAnalgesics, OpioidMorphine Derivativeschronic painopioidsrestless legs syndrometaperwithdrawal

Identifiers

PMID36692170
PMCPMC10071383
OpenAlexW4317870148

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.